Micofenolato De Mofetilo Accord (Mycophenolate Mofetil)

Mycophenolate mofetil is converted in the body to mycophenolic acid, which blocks the enzyme inosine monophosphate dehydrogenase. This inhibition stops the synthesis of guanosine nucleotides needed for T‑ and B‑cell proliferation, thereby dampening the immune response that can lead to organ rejection.

The specific dose and dosing schedule are determined by the prescribing physician based on the patient’s transplant type, body weight, renal function, and other clinical factors. Patients should follow the exact regimen provided by their healthcare professional.

Safety data in pregnancy and lactation are limited. The drug is generally avoided during pregnancy unless the potential benefit justifies the risk to the fetus. Breastfeeding is not recommended while taking mycophenolate mofetil because the drug can be excreted in milk.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Compared with calcineurin inhibitors such as cyclosporine or tacrolimus, mycophenolate mofetil offers a different mechanism—targeting nucleotide synthesis rather than calcineurin signaling. It is often used in combination with those agents to achieve synergistic immunosuppression while potentially reducing the dose‑related toxicity of each individual drug.

The product should be stored at ambient temperature, below 25 °C, in its original container. Keep it away from moisture, direct sunlight, and excessive heat. Do not refrigerate or freeze unless specifically instructed on the label.

Micofenolato De Mofetilo Accord is taken orally, usually with food or a glass of water to lessen gastrointestinal irritation. The tablet should be swallowed whole and not split, crushed, or chewed unless the prescribing information states otherwise.

Serious risks include severe infections, bone‑marrow suppression leading to leukopenia or anemia, liver toxicity, and rare but life‑threatening conditions such as progressive multifocal leukoencephalopathy (PML). Patients should be monitored regularly for signs of infection, blood count changes, and liver function abnormalities.

Patients with known hypersensitivity to mycophenolate mofetil or any component of the formulation should avoid the drug. It is also contraindicated in individuals with uncontrolled severe infections, active malignancy, or those who are pregnant without a clear therapeutic justification.